000			02134 a2200601 4500
005			20250516042230.0
264		0	_c20120509
008			201205s 0 0 eng d
022			_a1930-739X
024	7		_a10.1038/oby.2011.152 _2doi
040			_aNLM _beng _cNLM
100	1		_aSathyanarayana, Padma
245	0	0	_aEffects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes. _h[electronic resource]
260			_bObesity (Silver Spring, Md.) _cDec 2011
300			_a2310-5 p. _bdigital
500			_aPublication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
650	0	4	_aAdiponectin _xblood
650	0	4	_aAdipose Tissue _xdrug effects
650	0	4	_aAlanine Transaminase _xblood
650	0	4	_aAspartate Aminotransferases _xblood
650	0	4	_aBiomarkers _xblood
650	0	4	_aBlood Glucose _xmetabolism
650	0	4	_aBody Mass Index
650	0	4	_aBody Weight _xdrug effects
650	0	4	_aDiabetes Mellitus, Type 2 _xdiet therapy
650	0	4	_aDrug Therapy, Combination
650	0	4	_aExenatide
650	0	4	_aFasting
650	0	4	_aFatty Acids, Nonesterified _xblood
650	0	4	_aGlucagon-Like Peptide-1 Receptor
650	0	4	_aGlycated Hemoglobin _xmetabolism
650	0	4	_aHumans
650	0	4	_aHypoglycemic Agents _xpharmacology
650	0	4	_aLiver _xdrug effects
650	0	4	_aMagnetic Resonance Spectroscopy
650	0	4	_aMetformin _xtherapeutic use
650	0	4	_aMiddle Aged
650	0	4	_aObesity _xcomplications
650	0	4	_aPPAR gamma _xagonists
650	0	4	_aPeptides _xpharmacology
650	0	4	_aPioglitazone
650	0	4	_aReceptors, Glucagon _xagonists
650	0	4	_aThiazolidinediones _xpharmacology
650	0	4	_aTriglycerides _xblood
650	0	4	_aVenoms _xpharmacology
700	1		_aJogi, Medhavi
700	1		_aMuthupillai, Raja
700	1		_aKrishnamurthy, Ramkumar
700	1		_aSamson, Susan L
700	1		_aBajaj, Mandeep
773	0		_tObesity (Silver Spring, Md.) _gvol. 19 _gno. 12 _gp. 2310-5
856	4	0	_uhttps://doi.org/10.1038/oby.2011.152 _zAvailable from publisher's website
999			_c20916143 _d20916143